✦ LIBER ✦

PCN11 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS AFTER FIRST-LINE FAILURE OF IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) IN AUSTRIA

✍ Scribed by JFS Logman; MJ Taylor; K Neumann; L Kutikova; KH Cerri; BA Van Hout; T Kühr

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN13 Cost-Effectiveness Analysis of Nil

✍ Niu, X.; Hay, J. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN2 COST-EFFECTIVENESS OF IMATINIB (GLE

✍ K El Ouagari; W Talbot; JF Baladi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

PCN34 BUDGET IMPACT ANALYSIS OF DASATINI

✍ E Asano; M Nita; A Moellmann-Coelho; R Rached; B Donato; E Rahal 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

PCN124 COST-UTILITY ANALYSIS OF DASATINI

✍ E Asano; M Nita; A Moellmann-Coelho; R Rached; B Donato; E Rahal 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

Cost-Utility Analysis of Dasatinib and N

✍ Kulpeng, Wantanee; Sompitak, Sumalai; Jootar, Saengsuree; Chansung, Kanchana; Te 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 433 KB

PCN86 Cost-Utility Analysis of Nilotinib

✍ Inocencio, T.J.; Seetasith, A.; Newland, A.; Bose, P.; Holdford, D. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB